Transgene announced that the first UK patient has been enrolled in the Phase I clinical trial of TG4050, Transgenes innovative individualized cancer immunotherapy, currently being evaluated in HPV-negative head and neck cancer patients. TG4050 is a therapeutic vaccine based on Transgenes myvac® technology platform, which leverages Transgenes proprietary technologies and cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient. The innovative approach behind TG4050 combines Transgenes expertise in virus-based immunotherapies, NECs longstanding AI technologies and the commitment of prestigious cancer care centers in the United Kingdom, the European Union, and the United States. The trial is led by the coordinating investigator Professor Christian Ottensmeier, Consultant Medical Oncologist at The Clatterbridge Cancer Centre and Professor of Immuno-Oncology at the University of Liverpool. In the UK, the trial is being conducted in Liverpool and in Southampton (at the Clatterbridge Cancer Centre NHS Foundation Trust, at Liverpool University Hospitals and at the University Hospital Southampton NHS Foundation Trust /University of Southampton).